ReleaseWire

Global Markets Direct's, 'Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Hyperglycemia - Pipeline Review, H2 2014', provides an overview of the Hyperglycemia's therapeutic pipeline.

OTC Medications in Indonesia by Mintel Market Sizes provides you with annual year-end market size data, most recently updated in 2014. This market covers analgesics, cough/cold/flu, gastro-intestinal, dermatological remedies and vitamins and minerals. It excludes products which require prescriptions but includes pharmacy approved. Market size comprises sales through all retail channels including direct to consumer. Market size for OTC Medications in Indonesia is given in IDR with a minimum of five years' historical data. Market Forecast is provided for five years. Included with this snapshot is socio-economic data for Indonesia. Population, Consumer Price Index (CPI), Gross Domestic Product (GDP), Exchange Rates.

Global Markets Direct's, 'Alba Therapeutics Corporation - Product Pipeline Review - 2014', provides an overview of the Alba Therapeutics Corporation's pharmaceutical research and development focus.

Glucosamine supplements are the most popular dietary additions to ease joint pain, but many consumers are confused about which form of glucosamine is the most beneficial. Numerous studies have demonstrated that glucosamine sulfate is more effective than glucosamine hydrochloride.

A large number of patients cannot take traditional anti-clotting drugs, such as warfarin, because of the risks of internal bleeding and drug interactions.

This report provides comprehensive information on the therapeutic development for Keloids, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keloids and special features on late-stage and discontinued projects.

Global Markets Direct's, 'Philogen S.p.A. - Product Pipeline Review - 2014', provides an overview of the Philogen S.p.A.'s pharmaceutical research and development focus.

Global Markets Direct's, 'PharmaNova Inc. - Product Pipeline Review - 2014', provides an overview of the PharmaNova Inc.'s pharmaceutical research and development focus.

OTC Medications in Poland by Mintel Market Sizes provides you with annual year-end market size data, most recently updated in 2014. This market covers analgesics, cough/cold/flu, gastro-intestinal, dermatological remedies and vitamins and minerals. It excludes products which require prescriptions but includes pharmacy approved. Market size comprises sales through all retail channels including direct to consumer. Market size for OTC Medications in Poland is given in PLN with a minimum of five years' historical data. Market Forecast is provided for five years. Included with this snapshot is socio-economic data for Poland. Population, Consumer Price Index (CPI), Gross Domestic Product (GDP), Exchange Rates.

Glucosamine and MSM (or Methylsulfonylmethane) are well-known ingredients in supplements that are believed to individually help reduce arthritis pain. However, several experts suggest that a combination of the two ingredients may be far more effective than each on their own.

Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

OTC Medications in Mexico by Mintel Market Sizes provides you with annual year-end market size data, most recently updated in 2014. This market covers analgesics, cough/cold/flu, gastro-intestinal, dermatological remedies and vitamins and minerals. It excludes products which require prescriptions but includes pharmacy approved. Market size comprises sales through all retail channels including direct to consumer. Market size for OTC Medications in Mexico is given in MXN with a minimum of five years' historical data. Market Forecast is provided for five years. Included with this snapshot is socio-economic data for Mexico. Population, Consumer Price Index (CPI), Gross Domestic Product (GDP), Exchange Rates.

DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), a clinical-stage oncology company, today announced the presentation of promising new data supporting the activity of its lead drug compound, VAL-083, in the treatment of non-small cell lung cancer (NSCLC) at the AACR’s New Horizons in Cancer Research: Harnessing Breakthroughs – Targeting Cures. The conference takes place October 9th to 12th in Pudong, Shanghai.

Orthopedic biomaterial deals with the physical and chemical properties of the material that is implanted into the human body as constituents of devices. The material implanted is designed to perform specific biological functions by substituting or repairing the damaged tissues such as cartilage, bone, ligaments, and tendons. Bone and joint-related degenerative problems affect millions of people worldwide; this is one of the major causes for half of all chronic diseases in people aged above 50 globally. Diseases and conditions in orthopedic such as osteoporosis, arthritis, tumors, trauma, hip and knee replacement, fractures, neck problems, and soft tissue injuries are the main reasons for using temporary, permanent, or biodegradable devices. Therefore, orthopedic biomaterials play a vital role in the implantation of such devices and provide beneficial objective for physiological requirements with the complex interplay of materials properties.

Global Markets Direct's, 'Acucela Inc. - Product Pipeline Review - 2014', provides an overview of the Acucela Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Epilepsy - Pipeline Review, H2 2014', provides an overview of the Epilepsy's therapeutic pipeline.

A man's failure to sustain an erection that is adequate enough for sexual activity is known as erectile dysfunction. It also refers to the inconsistency to do so, or the inability to endure it for an extended period. Erectile dysfunction can be due to a number of reasons including aging, high blood pressure, diabetes mellitus, depression, smoking, nerve or spinal cord damage, alcoholism, and low testosterone levels. Treatments for erectile dysfunction include adopting a healthy lifestyle, oral phosphodiesterase type 5 (PDE5) inhibitors, vacuum devices, and surgery. Erectile dysfunction affects the quality of life and leads to stress, anxiety, and self-confidence problems. New research is undergoing in the field of erectile dysfunction to find more enhanced and effective therapies.

Global Markets Direct's, 'Diarrhea - Pipeline Review, H2 2014', provides an overview of the Diarrhea's therapeutic pipeline.

Global Markets Direct's, 'Myelodysplastic Syndrome - Pipeline Review, H2 2014', provides an overview of the Myelodysplastic Syndrome's therapeutic pipeline.

Although pediatrics represent around two-fifths of the global population the market for pediatric medicines remains relatively small (accounting for<10% of global pharmaceutical sales). Until pediatric legislation was introduced in the US (1997) and EU (2007) there has been little incentive for the pharma industry to evaluate drugs in children due to the low medical need of chronic illnesses and the high off-label use of generic drugs (Milne & Bruss, 2008).

Adaptive Licensing (AL) is a flexible approach to drug development and regulation, with two live pilot schemes accepted by the European Medicines Agency (EMA). The system acknowledges that levels of uncertainty will always surround innovative treatments. An initial license is granted at an earlier stage than possible under the traditional system, with less clinical information from Randomized Controlled Trials (RCTs). After the initial license is granted, the entry to market is heavily restricted, and the patient population is carefully monitored through observational studies, electronic devices and registries. Data from ongoing RCTs, and the more robust data from post-license surveillance studies are used to determine full license permission. By improving the alignment of stakeholder needs in a fluid system, overall costs and patient access times can be reduced. However, uncertainty still exists around the approach, and it is clear that cultural and political changes will be necessary to realize the full potential of AL.

GlobalData's clinical trial report, "Neonatal Respiratory Distress Syndrome Global Clinical Trials Review, H2, 2014" provides data on the Neonatal Respiratory Distress Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neonatal Respiratory Distress Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neonatal Respiratory Distress Syndrome. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'Alopecia - Pipeline Review, H2 2014', provides an overview of the Alopecia's therapeutic pipeline.

Medicortex Finland Oy is a start-up pharmaceutical company focused on the treatment of neurodegenerative conditions. The company is developing a pharmaceutical therapy, which will limit the long-term effects of brain injuries, including the types of severe brain trauma that veterans may have received in combat. The Company’s other mission is to identify a biomarker and a diagnostic test to reliably establish the severity and extent of a brain injury. The company has recently launched a crowd funding campaign accessible at http://privatequity.biz/stock/medicortex-finland-oy/